Detailed Information on Publication Record
2007
Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT)
DOUBEK, Michael, Jan MUŽÍK, Tomáš SZOTKOWSKI, Vladimír KOZA, Petr CETKOVSKÝ et. al.Basic information
Original name
Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT)
Name in Czech
Je FLT3 tandemová duplikace významným indikátorem pro alogenní transplantaci u akutní myeloidní leukémie? Analýza pacientů registru akutních leukémií (ALERT)
Name (in English)
Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT)
Authors
DOUBEK, Michael (203 Czech Republic, guarantor), Jan MUŽÍK (203 Czech Republic), Tomáš SZOTKOWSKI (203 Czech Republic), Vladimír KOZA (203 Czech Republic), Petr CETKOVSKÝ (203 Czech Republic), Tomáš KOZÁK (203 Czech Republic), Pavel ŽÁK (203 Czech Republic), Jaroslava VOGLOVÁ (203 Czech Republic), Soňa ŠTRUNCOVÁ (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic) and Karel INDRÁK (203 Czech Republic)
Edition
Neoplasma, Bratislava, 2007, 0028-2685
Other information
Language
Czech
Type of outcome
Článek v odborném periodiku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 1.208
RIV identification code
RIV/00216224:14110/07:00032737
Organization unit
Faculty of Medicine
UT WoS
000246073100014
Keywords in English
HUMAN HEMATOLOGIC MALIGNANCIES; ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; FLT3-ACTIVATING MUTATIONS; PROGNOSTIC-SIGNIFICANCE; RISK GROUP; 12 TRIALS; AML 10; CYTOGENETICS; EXPRESSION
Tags
Změněno: 1/4/2010 09:37, prof. RNDr. Ladislav Dušek, Ph.D.
V originále
AML patients, we performed an analysis of all patients with FLT3 mutations registered in the Czech Acute Leukemia Clinical Register (ALERT) from 2003 till the end of 2005. Within the mentioned period 170 patients with AML of median age 56 years (23-77) were investigated for FLT3 mutation, within them 36 cases (21 %) with FLT3 mutations (32 FLT3 ITD and 4 FLT3 D835) were found.Out of FLT3 ITD positive patients 13 had allogeneic transplantation, 20 patients with mutations of FLT3 were treated with chemotherapy without transplantation. Results of the treatment of these patients were compared with the results of the group of patients without FLT3 mutation, which was according to other characteristics identical with the group of patients with FLT3 mutations (n=134). Median overall survival (OS) was significantly shorter for patients with FLT3 ITD (34.8 weeks) than for those without FLT3 mutations (67.7 weeks; P=0.028). Median OS of patients with FLT3 ITD who had allogeneic transplantation was 42.5 weeks; median OS of patients with FLT3 ITD treated only with chemotherapy was 29.6 weeks (P=0.362). After allogeneic transplantation, median OS of FLT3 mutations negative patients was similar to FLT3 ITD positive patients (46.7 versus 42.5 weeks; P=0.443). Our results suggest that at present there is no strong evidence that FLT3 status alone should influence the decision to proceed to allogeneic transplantation in AML patients.
In English
AML patients, we performed an analysis of all patients with FLT3 mutations registered in the Czech Acute Leukemia Clinical Register (ALERT) from 2003 till the end of 2005. Within the mentioned period 170 patients with AML of median age 56 years (23-77) were investigated for FLT3 mutation, within them 36 cases (21 %) with FLT3 mutations (32 FLT3 ITD and 4 FLT3 D835) were found.Out of FLT3 ITD positive patients 13 had allogeneic transplantation, 20 patients with mutations of FLT3 were treated with chemotherapy without transplantation. Results of the treatment of these patients were compared with the results of the group of patients without FLT3 mutation, which was according to other characteristics identical with the group of patients with FLT3 mutations (n=134). Median overall survival (OS) was significantly shorter for patients with FLT3 ITD (34.8 weeks) than for those without FLT3 mutations (67.7 weeks; P=0.028). Median OS of patients with FLT3 ITD who had allogeneic transplantation was 42.5 weeks; median OS of patients with FLT3 ITD treated only with chemotherapy was 29.6 weeks (P=0.362). After allogeneic transplantation, median OS of FLT3 mutations negative patients was similar to FLT3 ITD positive patients (46.7 versus 42.5 weeks; P=0.443). Our results suggest that at present there is no strong evidence that FLT3 status alone should influence the decision to proceed to allogeneic transplantation in AML patients.
Links
| MSM0021622412, plan (intention) |
|